This technology identifies both a bone-derived and a non-bone-derived hormone that restores muscle function and muscle mass in sarcopenia.
Sarcopenia is the most significant cause of disability and frailty in the elderly. Current treatment options are focused on symptom management rather than treating the biology underlying the loss of muscle mass and strength. There remains a need for the development of therapeutics that efficaciously prevent or treat sarcopenia in at-risk individuals.
This technology describes a function of osteocalcin, a bone-derived hormone with pleiotropic effects, as well as non-osteocalcin-based agents in reversing muscle dysfunction in sarcopenia. In mouse models of sarcopenia, administration of osteocalcin both prevents and ameliorates loss of muscle function and muscle mass. As such, this technology identifies a potential therapeutic strategy for treating sarcopenia and age-related physical frailty.
Patent Pending (US20220106376)
Patent Pending (US20220106372)
IR CU20231
Licensing Contact: Jerry Kokoshka